

4 March 2025

Treatment of Melanoma

I have a freedom of information request regarding the treatment of melanoma.

1. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage) :

- | | |
|---|---------------|
| • Cobimetinib | <5 |
| • Dabrafenib | <5 |
| • Dabrafenib + Trametinib | <5 |
| • Dacarbazine | <5 |
| • Denosumab | Unavailable |
| • Encorafenib + Binimetinib | 7 |
| • Ipilimumab monotherapy | <5 |
| • Ipilimumab + Nivolumab | 13 |
| • Nivolumab monotherapy | 11 |
| • Nivolumab + Relatlimab | <5 |
| • Pembrolizumab | 44 |
| • Trametinib | <5 |
| • Vemurafenib | <5 |
| • Vemurafenib + Cobimetinib | <5 |
| • Other active systemic anti-cancer therapy: | |
| Tebentafusp | <5 |
| Tebentafusp MAP | <5 |
| • Palliative care only | Not available |

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act, as the small numbers involved could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

2. How many patients have started treatment for melanoma for the first time in the last 3 months with the following treatments (*Please only count patients who have not been treated with any of these treatments for melanoma previously*)

- | | |
|--|----|
| • Ipilimumab (monotherapy) | <5 |
| • Nivolumab (monotherapy) | <5 |
| • Nivolumab AND Ipilimumab (combination) | 10 |
| • Nivolumab AND Relatlimab | <5 |
| • Pembrolizumab | 6 |

4 March 2025

- **Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib / Vemurafenib /Vemurafenib AND Cobimetinib)** <5
- **Other active systemic anti-cancer therapy** <5
- **Palliative care only** Not available